SAD and MAD Study of AKB-9090 in Healthy Adult Participants
← catalyst calendarNCT07429006 · readout ≤ 73 d
Sponsored by Akebia Therapeutics (industry) · AKBA — their whole pipeline →. With Emerald Clinical Trials.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
70estimated
Sites
1
Country
New Zealand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-16 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: AKB-9090
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of participants who will report serious Treatment emergent adverse events (TEAEs) and TEAEs
measured From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Physical Examinations
measured From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Vital Signs
measured From First Dose to Day 7
Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG)
measured From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Chemistry parameters
measured From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Hematology Parameters
measured from first dose to Day 7
Number of Participants with Clinically Significant Changes in Lipid Parameters
measured From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Coagulation Parameters
measured From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Urinalysis Parameters
measured From First Dose to Day 7
Permalink · AKBA's whole pipeline · Catalyst calendar · Every registered study · What changed